Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication

Andersen, 2020, The proximal origin of SARS-CoV-2, Nat. Med., 26, 450, 10.1038/s41591-020-0820-9 Wehbe, 2020, Molecular insights into SARS COV-2 interaction with cardiovascular disease: role of RAAS and MAPK signaling, Front. Pharmacol., 11, 10.3389/fphar.2020.00836 Low, 2020, Drug repositioning: new approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak, Viruses, 12, 1058, 10.3390/v12091058 Sharma, 2021, COVID-19: a review on the novel coronavirus disease evolution, transmission, detectionControl and Prevention, 13, 202 Bello, 2020, Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach, J. Mol. Graph. Model., 101, 10.1016/j.jmgm.2020.107762 Bello, 2020, Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA, J. Mol. Model., 26, 10.1007/s00894-020-04600-4 Zanella, 2021, Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection, Pharmaceuticals, 14, 454, 10.3390/ph14050454 Jeon, 2020, Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs, Antimicrob. Agents Chemother., 64, 10.1128/AAC.00819-20 Laing, 2017, Ivermectin – old drug, new Tricks?, Trends Parasitol., 33, 463, 10.1016/j.pt.2017.02.004 Õmura, 2008, Ivermectin: 25 years and still going strong, Int. J. Antimicrob. Agents, 31, 91, 10.1016/j.ijantimicag.2007.08.023 Campbell, 1983, Ivermectin: a potent new antiparasitic agent, Science, 221, 823, 10.1126/science.6308762 Õmura, 2004, The life and times of ivermectin — a success story, Nat. Rev. Microbiol., 2, 984, 10.1038/nrmicro1048 Ashour, 2019, Ivermectin: from theory to clinical application, Int. J. Antimicrob. Agents, 54, 134, 10.1016/j.ijantimicag.2019.05.003 Burnham, 2004, Review: the delivery of ivermectin (MectizanR), Trop. Med. Int. Health, 9, A26, 10.1111/j.1365-3156.2004.01211.x Muñoz-Muñoz, 2021, Repurposing avermectins and milbemycins against mycobacteroides abscessus and other nontuberculous mycobacteria, Antibiotics, 10, 381, 10.3390/antibiotics10040381 Tang, 2021, Ivermectin, a potential anticancer drug derived from an antiparasitic drug, Pharmacol. Res., 163, 10.1016/j.phrs.2020.105207 Yin, 2015, DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis, Brain, 138, 2553, 10.1093/brain/awv167 Jin, 2015, Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease, Sci. Rep., 5, 10.1038/srep17288 Mastrangelo, 2012, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J. Antimicrob. Chemother., 67, 1884, 10.1093/jac/dks147 Wagstaff, 2012, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem. J., 443, 851, 10.1042/BJ20120150 Caly, 2020, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir. Res., 178, 10.1016/j.antiviral.2020.104787 Wehbe, 2021, Repurposing ivermectin for COVID-19: molecular aspects and therapeutic possibilities, Front. Immunol., 12, 10.3389/fimmu.2021.663586 Campbell, 1981, An introduction to the avermectins, N. Z. Vet. J., 29, 174, 10.1080/00480169.1981.34836 Kaur, 2021, Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes, Pharmacol. Rep., 73, 736, 10.1007/s43440-020-00195-y Jans, 2020, Ivermectin as a broad-Spectrum host-directed antiviral: the real deal?, Cells, 9, 2100, 10.3390/cells9092100 Chaccour, 2020, Ivermectin and COVID-19: keeping rigor in times of urgency, Am. J. Trop. Med. Hyg., 102, 1156, 10.4269/ajtmh.20-0271 Kaddoura, 2020, COVID-19 therapeutic options under investigation, Front. Pharmacol., 11, 10.3389/fphar.2020.01196 Frieman, 2007, Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/golgimembrane, J. Virol., 81, 9812, 10.1128/JVI.01012-07 Wulan, 2015, Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA viruses, Front. Microbiol., 6, 10.3389/fmicb.2015.00553 Barrows, 2016, A screen of FDA-approved drugs for inhibitors of zika virus infection, Cell Host Microbe, 20, 259, 10.1016/j.chom.2016.07.004 Petersen, 2016, Zika virus, N. Engl. J. Med., 374, 1552, 10.1056/NEJMra1602113 Ji, 2020, Zika virus NS5 nuclear accumulation is protective of protein degradation and is required for viral RNA replication, Virology, 541, 124, 10.1016/j.virol.2019.10.010 Colpitts, 2012, West Nile virus: biology, transmission, and human infection, Clin. Microbiol. Rev., 25, 635, 10.1128/CMR.00045-12 Mastrangelo, 2012, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J. Antimicrob. Chemother., 67, 1884, 10.1093/jac/dks147 Salomon, 2009, The influenza virus enigma, Cell, 136, 402, 10.1016/j.cell.2009.01.029 Götz, 2016, Influenza a viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci. Rep., 6 Xiao, 2013, The human interferon-induced MxA protein inhibits early stages of influenza a virus infection by retaining the incoming viral genome in the cytoplasm, J. Virol., 87, 13053, 10.1128/JVI.02220-13 Zimmermann, 2011, The viral nucleoprotein determines mx sensitivity of influenza a viruses, J. Virol., 85, 8133, 10.1128/JVI.00712-11 Yip, 2018, Advancements in host-based interventions for influenza treatment, Front. Immunol., 9, 10.3389/fimmu.2018.01547 Smith, 2006, Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses, ACS Chem. Biol., 1, 217, 10.1021/cb600131q Yang, 2020, The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antivir. Res., 177, 10.1016/j.antiviral.2020.104760 Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270, 10.1038/s41586-020-2012-7 Shereen, 2020, COVID-19 infection: emergence, transmission, and characteristics of human coronaviruses, J. Adv. Res., 24, 91, 10.1016/j.jare.2020.03.005 Naqvi, 2020, Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis., 1866, 10.1016/j.bbadis.2020.165878 Fehr, 2015, Coronaviruses: an overview of their replication and pathogenesis, Coronaviruses, 1 Neuman, 2006, Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy, J. Virol., 80, 7918, 10.1128/JVI.00645-06 Sen Gupta, 2020, Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with in-vitro effective drug ivermectin, J. Biomol. Struct. Dyn., 1 Frieman, 2007, Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic Reticulum/Golgi membrane, J. Virol., 81, 9812, 10.1128/JVI.01012-07 Tian, 2021, RNA-dependent RNA polymerase (RdRp) inhibitors: the current landscape and repurposing for the COVID-19 pandemic, Eur. J. Med. Chem., 213, 10.1016/j.ejmech.2021.113201 Saha, 2021, The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2, Struct. Chem., 1 Mody, 2021, Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, Commun. Biol., 4, 10.1038/s42003-020-01577-x Jans, 2019, Inhibitors of nuclear transport, Curr. Opin. Cell Biol., 58, 50, 10.1016/j.ceb.2019.01.001 Caly, 2012, Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?, Antivir. Res., 95, 202, 10.1016/j.antiviral.2012.06.008 Yang, 2019, Novel flavivirus antiviral that targets the host nuclear transport importin α/β1 heterodimer, Cells, 8, 281, 10.3390/cells8030281 Waheed Shouman . Prophylactic Ivermectin in COVID-19 Contacts - Study Results - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/results/NCT04422561 (Accessed Jun 10, 2021). Hariyanto, 2021, Ivermectin and outcomes from Covid-19 pneumonia: a systematic review and meta-analysis of randomized clinical trial studies, Rev. Med. Virol. Swargiary, 2020 Matsuyama, 2020, An aberrant STAT pathway is central to COVID-19, Cell Death Differ., 27, 3209, 10.1038/s41418-020-00633-7 Park, 2020, Type I and type III interferons – induction, signaling, evasion, and application to combat COVID-19, Cell Host Microbe, 27, 870, 10.1016/j.chom.2020.05.008 Wang, 2017, Enterovirus 71 suppresses interferon responses by blocking Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling through inducing karyopherin-α1 degradation, J. Biol. Chem., 292, 10262, 10.1074/jbc.M116.745729 Wang, 2019, STAT3 regulates the type I IFN-mediated antiviral response by interfering with the nuclear entry of STAT1, Int. J. Mol. Sci., 20, 4870, 10.3390/ijms20194870 Finigan, 2012, Human epidermal growth factor receptor signaling in acute lung injury, Am. J. Respir. Cell Mol. Biol., 47, 395, 10.1165/rcmb.2012-0100TR Gupta, 2016, Plasminogen activator inhibitor-1 stimulates macrophage activation through toll-like Receptor-4, Biochem. Biophys. Res. Commun., 477, 503, 10.1016/j.bbrc.2016.06.065 Aluwihare, 2008, What the lung has taught us about latent TGF-β activation, Am. J. Respir. Cell Mol. Biol., 39, 499, 10.1165/rcmb.2008-0003ED Han, 2015, The acute respiratory distress syndrome: from mechanism to translation, J. Immunol., 194, 855, 10.4049/jimmunol.1402513 Dou, 2016, Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt Axis in breast cancer, Cancer Res., 76, 4457, 10.1158/0008-5472.CAN-15-2887 Choi, 2021, Understanding viral infection mechanisms and patient symptoms for the development of COVID-19 therapeutics, Int. J. Mol. Sci., 22, 1737, 10.3390/ijms22041737 Yi, 2020, Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies, Cell. Mol. Immunol., 17, 621, 10.1038/s41423-020-0458-z Luo, 2021, The potential involvement of JAK-STAT signalling pathway in the COVID-19 infection assisted by ACE2, Gene, 768, 10.1016/j.gene.2020.145325 Hennighausen, 2020 Choudhury, 2021, Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in-silico approach, Futur. Virol., 16, 277, 10.2217/fvl-2020-0342 Lehrer, 2020, Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2, In Vivo, 34, 3023, 10.21873/invivo.12134 Bello, 2021, Elucidation of the inhibitory activity of ivermectin with host nuclear importin α and several SARS-CoV-2 targets, J. Biomol. Struct. Dyn., 1 Silvestrini, 2021, The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors, Sci. Rep., 11, 10.1038/s41598-021-88630-9 Bello, 2020, Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach, J. Mol. Graph. Model., 101, 10.1016/j.jmgm.2020.107762 Zhang, 2020, Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors, Science, 368, 409, 10.1126/science.abb3405 Jin, 2020, Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors, Nature, 582, 289, 10.1038/s41586-020-2223-y Kneller, 2020, Room-temperature neutron and X-ray data collection of 3CL mprofrom SARS-CoV-2, Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 76, 483, 10.1107/S2053230X20011814 Yang, 2005, Design of wide-spectrum inhibitors targeting coronavirus main proteases, PLoS Biol., 3 Dai, 2020, Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease, Science, 368, 1331, 10.1126/science.abb4489 Nukoolkarn, 2008, Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors, J. Theor. Biol., 254, 861, 10.1016/j.jtbi.2008.07.030 Choy, 2020, Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro, Antivir. Res., 178, 10.1016/j.antiviral.2020.104786 Cao, 2020, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N. Engl. J. Med., 382, 1787, 10.1056/NEJMoa2001282 Cui, 2020, Recent Progress in the drug development targeting SARS-CoV-2 Main protease as treatment for COVID-19, Front. Mol. Biosci., 7, 10.3389/fmolb.2020.616341 Anand, 2003, Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs, Science, 300, 1763, 10.1126/science.1085658 Nukoolkarn, 2008, Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors, J. Theor. Biol., 254, 861, 10.1016/j.jtbi.2008.07.030 Jamalipour Soufi, 2020, Potential inhibitors of SARS-CoV-2: recent advances, J. Drug Target., 29, 349, 10.1080/1061186X.2020.1853736 Samaha, 2021, Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in Lebanon, Viruses, 13, 989, 10.3390/v13060989 Kampf, 2021, Ct values and infectivity of SARS-CoV-2 on surfaces, Lancet Infect. Dis., 21, 10.1016/S1473-3099(20)30883-5 Kory, 2021, Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19, Am. J. Ther., 28, e299, 10.1097/MJT.0000000000001377 Elgazzar, 2020 Héctor, 2020, Study of the efficacy and safety of topical ivermectin + iota-carrageenan in the prophylaxis against COVID-19 in health personnel, J. Biomed. Res. Clin. Investig., 2, 10.31546/2633-8653.1007 Camprubí, 2020, Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients, PLOS ONE, 15, 10.1371/journal.pone.0242184 Krolewiecki, 2021, Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial, EClinicalMedicine, 37, 10.1016/j.eclinm.2021.100959 López-Medina, 2021, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19, JAMA, 325, 1426, 10.1001/jama.2021.3071 Ramírez, 2021, Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?, EClinicalMedicine, 32, 10.1016/j.eclinm.2021.100744 Schmith, 2020, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin. Pharmacol. Ther., 108, 762, 10.1002/cpt.1889